Key clinical point: Pembrolizumab can induce lipodystrophy with severe metabolic complications.
Major finding: A 47-year-old woman received pembrolizumab to treat metastatic melanoma and developed immune-related generalized acquired lipodystrophy.
Study details: A case study involving a 47-year-old woman in remission after being diagnosed with BRAF-mutated, stage IV melanoma.
Disclosures: Two coauthors reported relationships with Merck, which markets pembrolizumab, as well as Bristol-Myers Squibb, Pierre Fabre, Takeda, Innate Pharma, LEO Pharma, Roche, GlaxoSmithKline, Novartis, and Amgen.
Delyon J et al. Br J Dermatol. 2019 May 11. doi: 10.1111/bjd.18124.